Agilent Technologies delivers essential analytical instruments and digital solutions for life sciences and diagnostics, demonstrating resilient profitability with consistent net income growth over the last three years.
The stock offers a compelling value proposition with consistent profitability growth and a resilient cash generation engine that supports substantial shareholder returns via buybacks and dividends. As life sciences R&D spending recovers, Agilent's diversified product portfolio positions it to capture market share against larger competitors with lower capital intensity.
Despite recent profit recovery, revenue remains volatile due to cyclical demand in the pharmaceutical sector and potential overhang from large patent expirations for key clients. High accounts receivable levels of $1.49 billion relative to cash reserves suggest exposure to payment delays or credit risks if the macroeconomic environment worsens.
Agilent Technologies (NYSE:A) is a global leader in life sciences, diagnostics, and electronic material testing solutions serving pharmaceutical, healthcare, and industrial markets. The company leverages its portfolio of instruments, software, and services to provide critical tools for drug discovery, clinical diagnostics, and quality assurance across diverse industries.
Agilent delivered a robust $1.30 billion net profit in 2025, reversing the slight revenue contraction seen in 2024 to reach $6.95 billion, indicating strong operational momentum. The company maintained healthy cash flow from operations of $1.56 billion while returning significant capital to shareholders through $425 million in share repurchases and dividends.
The global life sciences and diagnostics industry is experiencing a transition period where traditional hardware sales are stabilizing after pandemic-era spikes, with growth increasingly driven by software subscriptions and service contracts. Analysts expect steady double-digit growth in the electronic materials testing segment as demand for high-purity chemicals and advanced battery manufacturing expands.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $6.83B | $6.51B | $6.95B |
| Cost of Revenue | $3.37B | $2.98B | $3.31B |
| Gross Profit | $3.46B | $3.54B | $3.64B |
| Operating Expenses | $2.12B | $2.05B | $2.16B |
| Operating Income | $1.35B | $1.49B | $1.48B |
| R&D | $481.0M | $479.0M | $455.0M |
| G&A | $1.63B | $1.57B | $1.71B |
| Stock-Based Comp | $111.0M | $129.0M | $128.0M |
| D&A | $271.0M | $257.0M | $288.0M |
| Depreciation | $128.0M | $149.0M | $178.0M |
| Amortization | $140.0M | $105.0M | $105.0M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-11.0M | $33.0M | $-44.0M |
| Interest Expense | $95.0M | $96.0M | $112.0M |
| Interest Income | $51.0M | $80.0M | $62.0M |
| Pre-Tax Income | $1.34B | $1.52B | $1.44B |
| Income Tax | $99.0M | $232.0M | $132.0M |
| Continuing Ops | $1.24B | $1.29B | $1.30B |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.24B | $1.29B | $1.30B |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $1.24B | $1.29B | $1.30B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $4.19B | $3.96B | $4.59B |
| Cash & Equivalents | $1.59B | $1.33B | $1.79B |
| Accounts Receivable | $1.29B | $1.32B | $1.49B |
| Inventory | $1.03B | $972.0M | $1.02B |
| Other Current Assets | $274.0M | $334.0M | $293.0M |
| Long-Term Assets | $6.58B | $7.89B | $8.13B |
| PP&E (Net) | $1.27B | $1.78B | $2.02B |
| Intangibles | $475.0M | $547.0M | $445.0M |
| Goodwill | $3.96B | $4.48B | $4.47B |
| Operating Leases | $154.0M | $177.0M | $183.0M |
| LT Investments | $164.0M | $175.0M | $133.0M |
| Other LT Assets | $554.0M | $733.0M | $876.0M |
| Total Assets | $10.76B | $11.85B | $12.73B |
| Current Liabilities | $1.60B | $1.90B | $2.35B |
| Accounts Payable | $418.0M | $540.0M | $570.0M |
| Current Leases | $46.0M | $42.0M | $44.0M |
| Taxes Payable | $73.0M | $152.0M | $143.0M |
| Other Current Liab | $1.07B | $1.16B | $1.59B |
| Long-Term Liabilities | $3.31B | $4.05B | $3.64B |
| LT Operating Leases | $118.0M | $142.0M | $145.0M |
| Other LT Liab | $3.04B | $3.80B | $3.47B |
| Total Liabilities | $4.92B | $5.95B | $5.99B |
| Shareholders' Equity | $5.84B | $5.90B | $6.74B |
| Paid-In Capital | $5.39B | $5.45B | $5.58B |
| Retained Earnings | $782.0M | $750.0M | $1.39B |
| AOCI | $-327.0M | $-305.0M | $-226.0M |
| Total L&E | $10.76B | $11.85B | $12.73B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.24B | $1.29B | $1.30B |
| Non-Cash Adjustments | $476.0M | $-106.0M | $-627.0M |
| Working Capital Changes | $56.0M | $568.0M | $883.0M |
| Cash from Operations | $1.77B | $1.75B | $1.56B |
| Capital Expenditures | $298.0M | $378.0M | $407.0M |
| Cash from Investing | $-310.0M | $-1.26B | $-394.0M |
| Debt Issuances | $0 | $1.20B | $4.0M |
| Debt Repayments | $0 | $600.0M | $3.0M |
| Share Buybacks | $575.0M | $1.15B | $425.0M |
| Dividends Paid | $265.0M | $274.0M | $282.0M |
| Cash from Financing | $-930.0M | $-752.0M | $-715.0M |
| FX Effect | $5.0M | $-2.0M | $9.0M |
| Net Change in Cash | $537.0M | $-261.0M | $459.0M |
| Beginning Cash | $1.06B | $1.59B | $1.33B |
| Ending Cash | $1.59B | $1.33B | $1.79B |
The company's revenue streams are primarily driven by its Life Sciences portfolio (life science products and services), Diagnostics segment (instruments for infectious disease detection and genetic testing), and Electronic Materials Testing solutions used in semiconductor and battery manufacturing.
Investors should monitor potential slowdowns in R&D spending by biotech clients impacting equipment sales, regulatory changes affecting diagnostic reimbursement rates, currency headwinds given the company's global operations, and supply chain disruptions affecting complex instrument manufacturing.
Agilent benefits from a deep installed base of instruments creating recurring service revenue, high switching costs due to specialized calibration and software ecosystems, and strong brand recognition that allows for premium pricing in the global life sciences market.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.